Posts Tagged ‘obesity’

While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]

Reject the binary. This cry is a response to simplistic, dichotomous thinking that seems to be ruling the day in so many contexts right now. It’s taking us on quite a number of dead-end journeys. One of these is the false dichotomy that suggests we must choose between providing care for obesity or for disordered […]

As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]

Thoughtful reporting by Jackie Snow in the New York Times prompts us to wonder about the possibility of a “contagion effect” from GLP-1s in families. When a parent receives highly effective treatment for obesity, what might the effect be on other family members? Of course, any answers to this question come from anecdotal observations. They […]

It is undeniable that obesity is a complex, chronic disease. When we gather people from all over the world who understand obesity, this is the number one thing everyone can agree upon. And yet, when we sit down to talk about models for health systems delivering obesity care, it is more likely that folks who […]

Honestly, we cannot figure out why this basic fact of obesity treatment seems so hard for so many people to grasp. New, advanced medicines for obesity don’t work well when a person doesn’t take them. A new study in Obesity drives this point home. Hamlet Gasoyan and colleagues found that discontinuations and sub-optimal dosing of […]

Yesterday, Metsera presented investors with topline data from phase one studies of a new amylin analog for obesity that promises monthly dosing. This is an early stage drug known only by its code name – MET-233i. Metsera is a young biotech company, founded in 2022. The big news here: 8.4% placebo-subtracted weight loss after 36 […]

So many people are chasing the concept of precision medicine for obesity. Because we can easily imagine that the rewards will be great. Right now, in treating obesity the clinical approach is something of a trial and error process. But the wish is to be able to assess a patient and from the start have […]

This headline from the University of Oklahoma captured our attention: “Fatty acid in olive oil drives obesity.” It was even more attractive when we read and understood this was not more of the linoleic acid and seed oils dogma bubbling up. It was a headline prompted by a new study of oleic acid and molecular […]

Mental health often, but not always, improves after metabolic and bariatric surgery. But new research tells us that this is not really a direct consequence of weight reduction. Instead, it seems that better mental health very likely comes from the reduction in experiences of weight stigma. In fact, Larissa McGarrity and colleagues found that the […]